<DOC>
	<DOCNO>NCT01413035</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy mesenchymal stem cell ( MSCs ) derive human umbilical cord/placenta dose 1.0E+6 MSC/kg type 2 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Study Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells Treat Type 2 Diabetes</brief_title>
	<detailed_description>1 . Intervention Details : Biological : umbilical cord/placenta-derived mesenchymal stem cell ; Drug : 1 . Oral Hypoglycemic Drugs , Dimethylbiguanide , Glurenorm Acarbose , et al . 2 . Insulins . 1 . 1st transplantation : finishing require examines accord protocol Day 0 , umbilical cord/placenta-derived MSCs transplant intravenously . 2 . 2nd transplantation : finishing required examines Day 90 , umbilical cord/placenta-derived-MSCs transplant intravenously effect MSC well . 3 . At time , patient continue take oral hypoglycemic drug , insulin combination oral hypoglycemic drug insulins patient take control high blood sugar Day 0 1 year . But dose oral hypoglycemic drug insulin regulate accord level blood sugar . 2 . Detailed Description : 1 . To evaluate feasibility safety transplantation treatment use umbilical cord/placenta-derived mesenchymal stem cell patient type 2 diabetes mellitus undergoing oral hypoglycemic drug , insulin combination oral hypoglycemic drug insulin . 2 . To assess efficacy transplantation treatment use umbilical cord/placenta-derived mesenchymal stem cell patient type 2 diabetes mellitus undergoing oral hypoglycemic drug , insulin combination oral hypoglycemic drug insulin . 3 . This study last 2 3 year . Participants randomly assign receive either MSC transplant oral hypoglycemic drug MSC transplant insulin MSC transplant combination oral hypoglycemic drug insulin ( experimental group ) oral hypoglycemic drug insulins combination oral hypoglycemic drug insulin ( control group ) . Patients undergo MSC transplant start study Day 0 take oral hypoglycemic drug , insulin combination oral hypoglycemic drug insulin 1 year . As control , patient take oral hypoglycemic drug , insulin combination oral hypoglycemic drug insulin 1 year . At time , dose oral hypoglycemic drug insulin regulate accord level blood sugar . After 3 month , patient receive second MSC transplantation . After six twelve month first transplantation , patient evaluate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Free take part study ability provide write informed consent Type 2 diabetes mellitus ( guideline WHO , 1999 ) Age 1880 year old , Male/Female 19≤Body mass index ( BMI ) ≤30㎏/㎡ Fast blood glucose ( FBG ) ≥7.0 mmol/L , HbAc1≥7％ Intravenous insulin tolerance test（ITT）indicate patient insulin resistance Not pregnant nursing No moderate sever organ dysfunction : Ejection fraction &gt; 45 % ; Creatinine &lt; 176 mmol/L No active severe viral fungus infection Severe concurrent medical condition ( e.g. , serious heart disease , lung disease , hematopoietic dysfunction , liver dysfunction , kidney dysfunction ) Active infection require treatment Unexplained febrile illness Known immunosuppressive disease , e.g . HIV infection , hepatitis B C infection Psychiatric condition would limit informed consent Patient enrol another clinical trial study within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Medicines : Oral Hypoglycemic Drugs Insulins .</keyword>
	<keyword>Umbilical Cord/placenta-Derived MSC</keyword>
	<keyword>Transplantation</keyword>
</DOC>